Comment on “Aldosterone Synthase Inhibition in Kidney Transplantation: Class Rationale, Translational Promise, and the Limits of Current Evidence”
Clinical Transplantation · 2026-11 · 40 (11)
DOI: 10.1111/ctr.70700 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical Transplantation, online erschienen am 17.11.2026. Verfasst von Shubham Singh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India.
- Faculty of Pharmaceutical Sciences, DAV University, Punjab, India.
- Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, India.
Zitieren
APA
Singh, S., Bhardwaj, S., & Sharma, A. K. (2026). Comment on “Aldosterone Synthase Inhibition in Kidney Transplantation: Class Rationale, Translational Promise, and the Limits of Current Evidence”. Clinical Transplantation, 40(11). https://doi.org/10.1111/ctr.70700
Vancouver
Singh S, Bhardwaj S, Sharma AK. Comment on “Aldosterone Synthase Inhibition in Kidney Transplantation: Class Rationale, Translational Promise, and the Limits of Current Evidence”. Clinical Transplantation. 2026;40(11). doi:10.1111/ctr.70700
BibTeX
@article{Singh2026,
author = {Singh, Shubham and Bhardwaj, Sharill and Sharma, Arun Kumar},
title = {Comment on “Aldosterone Synthase Inhibition in Kidney Transplantation: Class Rationale, Translational Promise, and the Limits of Current Evidence”},
journal = {Clinical Transplantation},
year = {2026},
volume = {40},
number = {11},
doi = {10.1111/ctr.70700}
}
EUVIMED